Epoprostenol sodium for treatment of pulmonary arterial hypertension

The release of endogenous prostacyclin (PGI(2)) is depressed in patients with pulmonary arterial hypertension (PAH). PGI(2) replacement therapy by epoprostenol infusion is one of the best treatments available for PAH. Here, we provide an overview of the current clinical data for epoprostenol. Epopro...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yukihiro, Nakamura, Kazufumi, Akagi, Satoshi, Sarashina, Toshihiro, Ejiri, Kentaro, Miura, Aya, Ogawa, Aiko, Matsubara, Hiromi, Ito, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437604/
https://www.ncbi.nlm.nih.gov/pubmed/25999730
http://dx.doi.org/10.2147/VHRM.S50368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437604/
https://www.ncbi.nlm.nih.gov/pubmed/25999730
http://dx.doi.org/10.2147/VHRM.S50368

Ejemplares similares